HYFT MindWalk Holdings Corp.

NEUTRAL Impact: 4/10 6-K
Horizon months Filed May 18, 2026 Processed 27d 18h ago SEC 0001193125-26-228179
Notable filing: 6-K
Latest settled — T+5d
HYFT ▲ +29.37% at T+5d
NEUTRAL call ✓ call won +29.37% · α vs SPY +27.75% · entry $1.26 → $1.63
Next anchor: T+20d tomorrow
Last close $1.56 (close Jun 12) · +23.81% from $1.26 entry
Entry anchored
May 18, 09:53 AM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.65%
$1.26
settled 27d ago
T+5d
+29.37%
call +29.37% · α +27.75%
$1.63
settled 20d ago
T+20d
call — · α —
tomorrow
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

MindWalk released a report documenting over 20 drug candidates originating from its antibody discovery work, with 10 programs in active Phase 1-3 trials at partners. The filing is a promotional update on historical scientific output and AI platform integration, with no new financial data, guidance, or material business developments.

Actionable Insight

This is a narrative/credibility-building filing with no hard catalysts. Monitor for partner clinical trial readouts or new partnership announcements that could validate the platform thesis. No immediate trading action warranted.

Key Facts

  • Over 20 discovery-originated drug candidates documented; 10 in active Phase 1-3 clinical trials
  • Partners include Annexon, argenx, Xencor, Cullinan Oncology, and others
  • Knowledge Graph: 660 million biological patterns, 25 billion relationships
  • Over 400 peer-reviewed publications and patents
  • No financial data, guidance, or material agreements disclosed

Financial Impact

No financial figures reported; filing is a retrospective scientific and platform update

Risk Factors

  • Partner programs may fail in clinical trials, undermining the discovery track record narrative
  • No revenue or near-term monetization path disclosed; cash burn and dilution risk remain
  • Forward-looking statements about AI platform value are unsubstantiated by financial results

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-228179
Document: press_release_may_18_202.htm0001193125-26-228179
Document: 0001193125-26-228179-index-headers.html0001193125-26-228179
Document: 0001193125-26-228179-index.html0001193125-26-228179
Document: 0001193125-26-228179.txt0001193125-26-228179
5 reports for HYFT
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HYFT — sortable, filterable
Type Now
Jun 12, 2026
2d ago
6-K
NEUTRAL ★ 2/10
$1.69 awaiting T+1awaiting T+1$1.56 (−7.69%)
Jun 10, 2026
4d ago
6-K
NEUTRAL ★ 4/10
$1.81 awaiting T+1awaiting T+1$1.56 (−13.81%)
Jun 2, 2026
12d ago
6-K
BULLISH ★ 6/10
$1.97 $1.80▼ −8.63%▼ −7.94%$1.56 (−20.81%)
May 27, 2026
18d ago
6-K
NEUTRAL ★ 4/10
$1.71 $1.79▲ +4.68%▲ +4.13%$1.56 (−8.77%)
May 18, 2026
27d ago
6-K
NEUTRAL ★ 4/10
$1.26 $1.26· 0.00%▲ +0.65%$1.56 (+23.81%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 4h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access